Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trialJonathan E. Rosenberg, Robert Dreicer, Petros Grivas et al.|The Lancet|2016Cited by 3.7k
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trialArjun Vasant Balar, Dean F. Bajorin, Matthew D. Galsky et al.|The Lancet|2016Cited by 2.2k
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort studyNicole M. Kuderer, Kerry L. Reynolds, Toni K. Choueiri et al.|The Lancet|2020Cited by 1.8k
Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trialMatthew D. Galsky, Enrique Grande, Jóse Ángel Arranz Arija et al.|The Lancet|2020Cited by 786
Treatment of Patients With Metastatic Urothelial Cancer “Unfit” for Cisplatin-Based ChemotherapyMatthew D. Galsky, Joaquim Bellmunt, Noah M. Hahn et al.|Journal of Clinical Oncology|2011Cited by 686